Eisei Hoshiyama

Dr. Eisei Hoshiyama

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
George ImatakaGeorge Imataka
George Imataka
SKShigeko Kuwashima
Shigeko Kuwashima
SHShujirou Hayashi
Shujirou Hayashi
KOKei Ogino
Kei Ogino
EHEisei Hoshiyama
Eisei Hoshiyama
HSHideaki Shiraishi
Hideaki Shiraishi
Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by a wide range of clinical manifestations, including café-au-lait macules, cutaneous neurofibromas, and an increased risk of certain malignancies. Historically, there has been no approved medical therapy specifically aimed at achieving tumor shrinkage or regression. Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection. Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1. This review highlights the pathophysiology of NF1 and the therapeutic role of MEK inhibitors and presents a detailed case study of a patient treated with selumetinib, a novel MEK inhibitor. While the therapeutic potential of selumetinib has been demonstrated in preclinical and clinical studies, including those involving Japanese patients, this review aims to evaluate its application in real-world clinical practice. A comprehensive discussion of the case study provides insights into the efficacy, safety, and clinical challenges associated with selumetinib treatment, offering valuable perspectives for its use in managing NF1.

7 January 2022 in Acute Medicine & Surgery
Verified
Journal Article
Open access
PDF file
EHEisei Hoshiyama
Eisei Hoshiyama
JKJunji Kumasawa
Junji Kumasawa
MUMasatoshi Uchida
Masatoshi Uchida
THToru Hifumi
Toru Hifumi
MTMoriya Takashi
Moriya Takashi
FCfor the Japan Resuscitation Council (JRC) Neuroresuscitation Task Force and the Guidelines Editorial Committee
for the Japan Resuscitation Council (JRC) Neuroresuscitation Task Force and the Guidelines Editorial Committee
Aim: Status epilepticus (SE) is a life‐threatening neurological emergency. There is insufficient evidence regarding which antiepileptic therapy is most effective in patients with benzodiazepine‐refractory convulsive SE. Therefore, this study aimed to evaluate intravenous phenytoin (PHT) and other intravenous antiepileptic medications for SE.Methods: We searched PubMed, the Cochrane Central Register of Controlled Trials, and Igaku Chuo Zasshi for published randomized controlled trials (RCTs) in humans up to August 2019. We compared outcomes between intravenous PHT and other intravenous medications. The important primary composite outcomes were the successful clinical cessation of seizures, mortality, and neurological outcomes at discharge. The reliability of the level of evidence for each outcome was compared using the Grading of Recommendations Assessment, Development, and Evaluation approach.Results: A total of 1,103 studies were identified from the databases, and 10 RCTs were included in the analysis. The ratio of successful clinical seizure cessation was significantly lower (risk ratio [RR] 0.89; 95% confidence interval [CI], 0.82–0.97) for patients treated with intravenous PHT than with other medications. When we compared mortality and neurological outcomes at discharge, we observed no significant differences between patients treated with PHT and those treated with other medications. The RRs were 1.07 (95% CI, 0.55–2.08) and 0.91 (95% CI, 0.72–1.15) for mortality and neurological outcomes at discharge, respectively.Conclusions: Our findings showed that intravenous PHT was significantly inferior to other medications in terms of the cessation of seizures. No significant differences were observed in mortality or neurological outcomes between PHT and other medications.

9 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
George ImatakaGeorge Imataka
George Imataka
SKShigeko Kuwashima
Shigeko Kuwashima
SHShujirou Hayashi
Shujirou Hayashi
KOKei Ogino
Kei Ogino
EHEisei Hoshiyama
Eisei Hoshiyama
HSHideaki Shiraishi
Hideaki Shiraishi
Neurofibromatosis Type 1 (NF1) is a genetic disorder characterized by a wide range of clinical manifestations, including café-au-lait macules, cutaneous neurofibromas, and an increased risk of certain malignancies. Historically, there has been no approved medical therapy specifically aimed at achieving tumor shrinkage or regression. Surgical intervention is often limited by factors such as the inaccessibility of the tumor location, involvement of critical tissues, suboptimal timing, or the inability to achieve complete resection. Recent advancements in targeted therapies, particularly MEK inhibitors, have introduced promising treatment options for patients with severe manifestations of NF1. This review highlights the pathophysiology of NF1, the therapeutic role of MEK inhibitors, and presents a detailed case study of a patient treated with selumetinib, a novel MEK inhibitor. While the therapeutic potential of selumetinib has been demonstrated in preclinical and clinical studies, including those involving Japanese patients, this review aims to evaluate its application in real-world clinical practice. A comprehensive discussion of the case study provides insights into the efficacy, safety, and clinical challenges associated with selumetinib treatment, offering valuable perspectives for its use in managing NF1.

20 March 2026 in Neurology and Clinical Neuroscience
Verified
Journal Article
Closed access
SYSungHoon Yang
SungHoon Yang
MUMasatoshi Uchida
Masatoshi Uchida
MHMana Higashihara
Mana Higashihara
EHEisei Hoshiyama
Eisei Hoshiyama
MIMasaaki Iwase
Masaaki Iwase
MKMichi Kawamoto
Michi Kawamoto

13 April 2026 in Neurology and Clinical Neuroscience
Verified
Journal Article
Closed access
MTMasaya Togo
Masaya Togo
HYHideto Yasuda
Hideto Yasuda
MUMasatoshi Uchida
Masatoshi Uchida
EHEisei Hoshiyama
Eisei Hoshiyama
HKHitoshi Kobata
Hitoshi Kobata
SYShoji Yokobori
Shoji Yokobori

19 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
George ImatakaGeorge Imataka
George Imataka
SKShigeko Kuwashima
Shigeko Kuwashima
KOKei Ogino
Kei Ogino
MOMayuko Okuya
Mayuko Okuya
SKSatomi Koyama
Satomi Koyama
HSHideaki Shiraishi
Hideaki Shiraishi
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the MECP2 gene on the X chromosome, primarily affecting females. It is characterized by developmental regression, stereotypic hand movements, seizures, and microcephaly due to decelerated head growth. However, atypical presentations, such as macrocephaly and hyperostosis frontalis interna (HFI), are rarely reported. HFI, defined as abnormal thickening of the frontal bone, is uncommon in pediatric populations and is often linked to metabolic disturbances, hormonal imbalances, or prolonged anti-seizure medication (ASM) use. We report the case of a 16-year-old girl with genetically confirmed Rett syndrome who presented with macrocephaly (+2.5 SD) and HFI. Genetic testing identified a pathogenic MECP2 mutation (c.882C>T, Arg270Stop), confirming the diagnosis. The patient’s early development was normal until 18 months, when developmental regression occurred, including loss of speech, impaired social interactions, and stereotypic hand movements. She was also diagnosed with central precocious puberty at age 9, treated with leuprorelin acetate for three years, during which her growth in height ceased. By age 16, her height was -2.6 SD. Brain MRI revealed thickening of the frontal bone and enlarged frontal sinuses, consistent with HFI. She experienced intractable epilepsy managed with multiple ASMs. Reduction in ASM doses improved dystonia but led to seizure recurrence. Additional evaluations revealed mild osteopenia and altered hormonal profiles, suggesting systemic effects of MECP2 dysfunction. This case highlights the expanded phenotypic spectrum of Rett syndrome, emphasizing the impact of MECP2 mutations on cranial growth and bone metabolism. Hormonal dysregulation and ASM use may contribute to these anomalies. Comprehensive evaluation and genetic testing are critical for differentiating Rett syndrome from overlapping conditions. A multidisciplinary approach is essential to manage rare manifestations and improve personalized care strategies.